Applied Clinical Trials Direct
Having trouble viewing this e-mail? Click here.
  September 5, 2013
In This Edition
News Roundup: Oncology Subject Recruitment Current Trends
Articles: Patient-First Approach to Improve Oncology Clinical Trials
Blog Posts: Redefining Cancer May Change Orphan Status of Cancer Drugs
Marketplace: Marketplace


News Roundup
bullet Oncology Subject Recruitment Current Trends
bullet Highlights: Go/No-Go Strategies in Oncology Trials
bullet WorldCare Clinical Introduces New Service for Oncology Imaging Studies
bullet Crown Bioscience Acquires Oncology Pre-Clinical Capabilities
bullet VirtualScopics Completes 6 Week Analysis of Phase III Breast Cancer Study

Sponsored
Update in Sleep Medicine: Impact of Nonrestorative Sleep for Mental Health Definition, Diagnosis, Evaluation, Treatment and Clinical Trials
On Demand Webcast
Register Free at: www.appliedclinicaltrialsonline.com/impact

Articles
bullet Patient-First Approach to Improve Oncology Clinical Trials


Blogs Posts
bullet Redefining Cancer May Change Orphan Status of Cancer Drugs

Sponsored
Applying Pharmacogenomics to enable real time decisions during drug development
Live Webcast: Tuesday, September 24, 2013 2:00 pm EDT
Click here to Register Free.

Events
bullet New Strategies to Expedite Go/ No Go Decisions in Oncology Trials
bullet Patient Engagement Forum

Sponsored
Implementing a new approach to study design: what can I expect?
Live Webcast: Thursday, September 12, 2013 and 11:00 am EDT
Register Free at www.appliedclinicaltrialsonline.com/studydesign

Marketplace

Sponsored
Covance(Xcellerate)
A lot of CROs offer databases. But only Covance offers Xcellerate®, a more strategic approach to Clinical Trial Optimization ®. Learn more.

Sponsored
Drug Development Strategies in China
Pharma and biotech firms who are relative newcomers to the Chinese market aren't aware that the regulatory climate has changed dramatically in recent years. SFDA approval times for Clinical Trials Approvals have dropped to 7-9 months for small molecules. There are also opportunities in China for sponsors that have not yet completed Phase II trials to create a parallel approval strategy. Even without final details (like final dosing) it’s possible to file a CTA for Phase III based on the most current early phase results. This parallel submission strategy can shave several months off the final approval time in China. Learn More


Sponsored
Implementing Rare Disease Registries: Unique Challenges & Proactive Solutions
Live Webinar: Wednesday, October 16, 2013 at 11:00 am EDT/ 4:00 BST/ 5:00 CEST
Register Free at: www.appliedclinicaltrialsonline.com/Unique


CHINA REPORT
China is the third largest pharmaceutical market in the world and will become the second largest ahead of Japan by 2015. Everything you need to know to do business in the country; key economic sector data and exclusive interviews from regional leaders. Read more

Follow Us

Ask The Editor

Lisa Henderson
Editor in Chief
lhenderson@advanstar.com